---
created: 2025-04-13
updated: 2025-04-13T10:52
id: q]E^lRwRb
specialty: cardio
specialty_id: 190
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/amboss
  - "source/ak-step1-v11:": 
  - theme/amboss::cardiovascular
  - "source/ak-step1-v11:": 
  - theme/b&b::03-biochem::05-lipids::03-lipid-drugs
  - "source/ak-step1-v11:": 
  - theme/firstaid::07-cardiovascular::05-pharm::10-lipid-lowering-agents::bile-acid-resins
  - "source/ak-step1-v11:": 
  - theme/nbme::29
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::09-cardiac
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::10-cardiac::10-bile-acid-resins
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::03-blood-&-inflammation::02-dyslipidemia-drugs::02-cholestyramine,-ezetimibe
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield
  - source/ak-step1-v11::^systems::cardio::pharmacology
type: flashcard
---

# Question
Bile acid resins (eg, cholestyramine) indirectly cause **increased** hepatic LDL receptor expression == decreasing cholesterol serum concentrations

---

# Answer
increased hepatic LDL receptors = upregulation == decreasing LDL blood concentrations; liver needs more cholesterol to synthesize bile acids    bile acid resins == 10-fold inc in bile acid excretion == hepatic synthesis of new bile acids, consuming liver cholesterol stires == upregulation of hepatic LDL receptors :: decreasing [blood LDL]; this reduction in hepatic cholesterol activates HMG CoA reductase == inc hepatic cholesterol synthesis    Combination therapy (statins + bile acid-binding resins eg cholestyramine) == synergistic reduction in plasma LDL level.